President and CEO, Mark Emalfarb, to speak at World Bio Markets at The RAI, Amsterdam, Netherlands
Panel Discussion: Reducing the Cost of Advanced Biofuels at 2:00 p.m. local time on March 5, 2014
JUPITER, Fla., February 18, 2014 – Dyadic International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb, will be discussing enzymes, catalysts and microorganisms that reduce the cost of advanced biofuels at the World Bio Markets exhibition at The RAI, Amsterdam, Netherlands during its Panel Discussion: Reducing the Cost of Advanced Biofuels at 2:00 p.m. local time on March 5, 2014.
All attendees of the World Bio Markets are invited to visit Dyadic’s stand located at Booth #E102 where Dyadic’s leading scientists and management will be available to discuss specific applications of Dyadic’s CMAX™ enzymes designed for biofuel, bio- based chemical and biogas applications. Dyadic’s industry leading CMAX™ enzymes are highly customizable, scalable and extremely robust: operating at broad temperature and pH ranges.
The World Bio Markets is Europe’s largest cross-value chain networking event and one of the bioproduct industry’s premier events, supporting the world’s development and search for alternative energy sources.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com.
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Dyadic International, Inc.
Michael J. Faby
Vice President and Chief Financial Officer